Mary Syto Selected Research

apricoxib

4/2014	A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
2/2011	Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary Syto Research Topics

Disease

2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2014 - 02/2011
2	Disease Progression 04/2014 - 02/2011
1	Hypophosphatemia 02/2011
1	Venous Thrombosis (Deep-Vein Thrombosis) 02/2011
1	Exanthema (Rash) 02/2011
1	Anemia 02/2011
1	Diarrhea 02/2011
1	Duodenal Ulcer (Curling's Ulcer) 02/2011
1	Fatigue 02/2011

Drug/Important Bio-Agent (IBA)

2	apricoxibIBA 04/2014 - 02/2011
2	Biomarkers (Surrogate Marker)IBA 04/2014 - 02/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2014 - 02/2011
1	ErbB Receptors (EGF Receptor)IBA 04/2014
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2014
1	PlatinumIBA 04/2014
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 02/2011
1	CreatinineIBA 02/2011
1	Pharmaceutical PreparationsIBA 02/2011
1	7- hydroxy- 5,11- dioxotetranorprostane- 1,16- dioic acidIBA 02/2011
1	ProstaglandinsIBA 02/2011

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 04/2014